Design Therapeutics, Inc.
DSGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001807120
No open-market purchases or sales by Design Therapeutics, Inc. insiders were filed in the last 90 days; 136 institutions reported holding it in 13F filings for Q2 2026, worth $626.4M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Design Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 95 | 1 | 100 | +6 |
| Shares | 32.1M | 2.30M | 32.0M | +2.24M (+7.5%) |
| Value | $107.5M | $7.72M | $172.3M | +$72.5M (+72.7%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (15)
Institutions that held Design Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 2,358,797 | $12.7M | 0.00% |
| EcoR1 Capital, LLC | 53,834 | $289.6K | 0.01% |
| SpiderRock Advisors, LLC | 26,965 | $145.1K | 0.00% |
| MetLife Investment Management | 19,334 | $104.0K | 0.00% |
| Manufacturers Life Insurance Company, The | 13,221 | $71.1K | 0.00% |
| SG Americas Securities, LLC | 12,289 | $66.0K | 0.00% |
| Paloma Partners Management Co | 11,902 | $64.0K | 0.00% |
| AJOVista, LLC | 10,319 | $55.5K | 0.24% |
| GAMMA Investing LLC | 417 | $2.24K | 0.00% |
| Newbridge Financial Services Group, Inc. | 300 | $1.61K | 0.00% |
| Capital Performance Advisors LLP | 143 | $769 | 0.00% |
| Sterling Capital Management LLC | 102 | $549 | 0.00% |
| Point72 (DIFC) Ltd | 67 | $362 | 0.00% |
| Farther Finance Advisors, LLC | 19 | $102 | 0.00% |
| Advisor Group Holdings, Inc. | 10 | $54 | 0.00% |
Sold out (9)
Institutions that held Design Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BML Capital Management, LLC | 421,749 | $1.41M |
| Wellington Management Group LLP | 256,627 | $859.7K |
| Opaleye Management Inc. | 205,000 | $686.8K |
| Verition Fund Management LLC | 27,045 | $90.6K |
| Cubist Systematic Strategies, LLC | 23,497 | $78.7K |
| Susquehanna International Group, LLP | 21,726 | $72.8K |
| Simplicity Wealth,LLC | 11,632 | $39.0K |
| Qube Research & Technologies Ltd | 2,986 | $10.0K |
| Point72 Asia (Singapore) Pte. Ltd. | 1,288 | $4.32K |
Not filed for Q3 2024 yet (1)
Institutions that held Design Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 2,304,948 | $7.72M |